Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming 'vaccine resistant malaria'

Parasite Immunology

Volumn 31, Issue 9, 2009, Pages 560-573

  Takala, S L ^a   Plowe, C V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Genetic diversity; Malaria vaccines; Molecular epidemiology; Plasmodium falciparum; Vaccine escape

Indexed keywords

ANTIGEN; APICAL MEMBRANE ANTIGEN 1; BLOOD GROUP ANTIGEN; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; FMP1 VACCINE ANTIGEN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; RECOMBINANT DNA VACCINE; SERINE REPEAT ANTIGEN 5; UNCLASSIFIED DRUG; VACCINE;

ALLELE; ANTIGENICITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; EVOLUTION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE TARGETING; GENETIC VARIABILITY; HUMAN; IMMUNITY; MALARIA; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NATURAL SELECTION; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; GENETIC VARIATION; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM;

PLASMODIUM FALCIPARUM;

EID: 68949126830     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01138.x     Document Type: Review

References (120)

1. Escalante AA, Lal AA Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 1998 149 : 189 202.
2. Beall B, McEllistrem MC, Gertz RE Jr., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006 44 : 999 1017.
3. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL Mason EO Jr. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 2006 25 : 301 305.
4. Brueggemann AB, Pai R, Crook DW Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007 3 : e168.
5. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002 185 : 820 827.
6. Enosse S, Dobano C, Quelhas D, et al. RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 2006 1 : e5.
7. Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009 27 : 3090 3098.
8. Ogutu BR, Apollo OJ, McKinney D, et al. MSP-1 Malaria Vaccine Working Group. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009 4 : e4708.
9. Blackman MJ, Heidrich HG, Donachie S, McBride JS Holder AA. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 1990 172 : 379 382.
10. Holder AA, Blackman MJ, Burghaus PA, et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz 1992 87 (Suppl. 3 37 42.
11. Nwuba RI, Sodeinde O, Anumudu CI, et al. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun 2002 70 : 5328 5331.
12. Patino JAG, Holder AA, McBride JS Blackman MJ. Antibodies that inhibit malaria Merozoite Surface Protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 1997 186 : 1689 1699.
13. Branch OH, Udhayakumar V, Hightower AW, et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 1998 58 : 211 219.
14. Branch OH, Oloo AJ, Nahlen BL, Kaslow D Lal AA. Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. J Infect Dis 2000 181 : 1746 1752.
15. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996 173 : 765 769.
16. John CC, O'Donnell RA, Sumba PO, et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 2004 173 : 666 672.
17. Okech BA, Corran PH, Todd J, et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004 72 : 1557 1567.
18. Riley EM, Allen SJ, Wheeler JG, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992 14 : 321 337.
19. Miller LH, Roberts T, Shahabuddin M McCutchan TF. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993 59 : 1 14.
20. Tanabe K, Mackay M, Goman M Scaife JG. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J Mol Biol 1987 195 : 273 287.
21. Takala S, Branch O, Escalante AA, Kariuki S, Wootton J Lal AA. Evidence for intragenic recombination in Plasmodium falciparum: identification of a novel allele family in block 2 of merozoite surface protein-1: Asembo Bay Area Cohort Project XIV. Mol Biochem Parasitol 2002 125 : 163 171.
22. Egan AF, Chappel JA, Burghaus PA, et al. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 1995 63 : 456 466.
23. Shi YP, Sayed U, Qari SH, et al. Natural immune response to the C-terminal 19-kiloDalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 1996 64 : 2716 2723.
24. Diallo TO, Spiegel A, Diouf A, Perraut R, Kaslow DC Garraud O. Short report: IgG1/IgG3 antibody responses to various analogs of recombinant ypfmsp119 - a study in immune adults living in areas of Plasmodium falciparum transmission. Am J Trop Med Hyg 2001 64 : 204 206.
25. Udhayakumar V, Anyona D, Kariuki S, et al. Identification of T and B cell epitopes recognized by humans in the C- terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 1995 154 : 6022 6030.
26. Takala SL, Coulibaly D, Thera MA, et al. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 2007 4 : e93.
27. Ferreira MU, Ribeiro WL, Tonon AP, Kawamoto F Rich SM. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 2003 304 : 65 75.
28. Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M Lal AA. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Mol Biochem Parasitol 1998 92 : 241 252.
29. Sakihama N, Kimura M, Hirayama K, et al. Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. Gene 1999 230 : 47 54.
30. Angov E, Aufiero BM, Turgeon AM, et al. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 2003 128 : 195 204.
31. Chenet SM, Branch OH, Escalante AA, Lucas CM Bacon DJ. Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J 2008 7 : 93.
32. Hodder AN, Crewther PE, Matthew ML, et al. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 1996 271 : 29446 29452.
33. Peterson MG, Marshall VM, Smythe JA, et al. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol 1989 9 : 3151 3154.
34. Narum DL Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994 67 : 59 68.
35. Mitchell GH, Thomas AW, Margos G, Dluzewski AR Bannister LH. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 2004 72 : 154 158.
36. Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002 419 : 520 526.
37. Silvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004 279 : 9490 9496.
38. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC Anders RF. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 2003 71 : 1416 1426.
39. Duan J, Mu J, Thera MA, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci USA 2008 105 : 7857 7862.
40. Eisen DP, Marshall VM, Billman-Jacobe H Coppel RL. A Plasmodium falciparum apical membrane antigen-1 (AMA-1) gene apparently generated by intragenic recombination. Mol Biochem Parasitol 1999 100 : 243 246.
41. Escalante AA, Grebert HM, Chaiyaroj SC, et al. Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol 2001 113 : 279 287.
42. Garg S, Alam MT, Das MK, et al. Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Malar J 2007 6 : 154.
43. Kocken CH, Narum DL, Massougbodji A, et al. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol Biochem Parasitol 2000 109 : 147 156.
44. Marshall VM, Zhang L, Anders RF Coppel RL. Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum. Mol Biochem Parasitol 1996 77 : 109 113.
45. Polley SD, Chokejindachai W Conway DJ. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 2003 165 : 555 561.
46. Remarque EJ, Faber BW, Kocken CH Thomas AW. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008 76 : 2660 2670.
47. Bai T, Becker M, Gupta A, et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci USA 2005 102 : 12736 12741.
48. Collins CR, Withers-Martinez C, Hackett F Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog 2009 5 : e1000273.
49. Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC Anders RF. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 2005 73 : 422 430.
50. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004 363 : 1860 1867.
51. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004 23 : 718 728.
52. Thomas AW, Trape JF, Rogier C, Goncalves A, Rosario VE Narum DL. High prevalence of natural antibodies against Plasmodium falciparum 83-kiloDalton apical membrane antigen (PF83/AMA-1) as detected by capture- enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg 1994 51 : 730 740.
53. Udhayakumar V, Kariuki S, Kolczack M, et al. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med Hyg 2001 65 : 100 107.
54. Hodder AN, Crewther PE Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001 69 : 3286 3294.
55. Kennedy MC, Wang J, Zhang Y, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002 70 : 6948 6960.
56. Kocken CH, Withers-Martinez C, Dubbeld MA, et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002 70 : 4471 4476.
57. Dutta S, Lee SY, Batchelor AH Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci USA 2007 104 : 12488 12493.
58. Healer J, Murphy V, Hodder AN, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 2004 52 : 159 168.
59. Remarque EJ, Faber BW, Kocken CH Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008 24 : 74 84.
60. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004 364 : 1411 1420.
61. Beier JC Vanderburg JP. Sporogonic development in the mosquito. In Sherman IW (eds Malaria Parasite Biology, Pathogenesis, and Protection. Washington, DC, ASM Press, 1998 : 63.
62. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984 225 : 593 599.
63. Escalante AA, Grebert HM, Isea R, et al. A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas - XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol 2002 125 : 83 90.
64. Rich SM, Hudson RR Ayala FJ. Plasmodium falciparum antigenic diversity: evidence of clonal population structure. Proc Natl Acad Sci USA 1997 94 : 13040 13045.
65. Ballou WR, Rothbard J, Wirtz RA, et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 1985 228 : 996 999.
66. Zhou Z, Xiao L, Branch OH, Kariuki S, Nahlen BL Lal AA. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Am J Trop Med Hyg 2002 66 : 7 12.
67. Sinnis P, Clavijo P, Fenyo D, Chait BT, Cerami C Nussenzweig V. Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J Exp Med 1994 180 : 297 306.
68. Sinnis P Nussenzweig V. Preventing sporozoite invasion of hepatocytes. In Hoffman SL (eds Malaria Vaccine Development: a Multi-Immune Response Approach. Washington, DC, ASM Press, 1996 : 17.
69. Aidoo M Udhayakumar V. Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. Parasitol Today 2000 16 : 50 56.
70. Alloueche A, Silveira H, Conway DJ, et al. High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol 2000 106 : 273 282.
71. de la Cruz VF, Lal AA McCutchan TF. Sequence variation in putative functional domains of the circumsporozoite protein of Plasmodium falciparum. Implications for vaccine development. J Biol Chem 1987 262 : 11935 11939.
72. Doolan DL, Saul AL Good ML. Geographically restricted heterogeneity of the Plasmodium falciparum CSP: relevance for vaccine development. Infect Immun 1992 60 : 675 682.
73. Good MF, Pombo D, Quakyi IA, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988 85 : 1199 1203.
74. Jalloh A, van Thien H, Ferreira MU, et al. Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam. J Clin Microbiol 2006 44 : 1229 1235.
75. Jongwutiwes S, Tanabe K, Hughes MK, Kanbara H Hughes AL. Allelic variation in the circumsporozoite protein of Plasmodium falciparum from Thai field isolates. Am J Trop Med Hyg 1994 51 : 659 668.
76. Kumkhaek C, Phra-Ek K, Renia L, et al. Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol 2005 175 : 3935 3939.
77. Lockyer M, Marsh K Newbold CI. Wild isolates of Plasmodium falciparum show extensive polymorphisms in T cell epitopes of the circumsporozoite protein. Mol Biochem Parasitol 1989 37 : 275 280.
78. Lockyer MJ Schwarz RT. Strain variation in the circumsporozoite protein gene of Plasmodium falciparum. Mol Biochem Parasitol 1987 22 : 101 108.
79. Shi YP, Alpers MP, Povoa MM Lal AA. Diversity in the immunodominant determinants of the circumsporozoite protein of Plasmodium falciparum parasites from malaria-endemic regions of Papua New Guinea and Brazil. Am J Trop Med Hyg 1992 47 : 844 851.
80. Weedall GD, Preston BM, Thomas AW, Sutherland CJ Conway DJ. Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol 2007 37 : 77 85.
81. de la Cruz VF, Maloy WL, Miller LH, Lal AA, Good MF McCutchan TF. Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. J Immunol 1988 141 : 2456 2460.
82. Guttinger M, Caspers P, Takacs B, et al. Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein. EMBO J 1988 7 : 2555 2558.
83. Udhayakumar V, Ongecha JM, Shi YP, et al. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur J Immunol 1997 27 : 1952 1957.
84. Zevering Y, Khamboonruang C Good MF. Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness. Eur J Immunol 1994 24 : 1418 1425.
85. Sutherland CJ, Drakeley CJ Schellenberg D. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar J 2007 6 : 161.
86. Okenu DM, Thomas AW Conway DJ. Allelic lineages of the merozoite surface protein 3 gene in Plasmodium reichenowi and Plasmodium falciparum. Mol Biochem Parasitol 2000 109 : 185 188.
87. Huber W, Felger I, Matile H, Lipps HJ, Steiger S Beck HP. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 1997 87 : 231 234.
88. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007 195 : 279 287.
89. Morimatsu K, Morikawa T, Tanabe K, Bzik DJ Horii T. Sequence diversity in the amino-terminal 47 kDa fragment of the Plasmodium falciparum serine repeat antigen. Mol Biochem Parasitol 1997 86 : 249 254.
90. Safitri I, Jalloh A, Tantular IS, et al. Sequence diversity in the amino-terminal region of the malaria-vaccine candidate serine repeat antigen in natural Plasmodium falciparum populations. Parasitol Int 2003 52 : 117 131.
91. Ravichandran M, Doolan DL, Cox-Singh J, Hoffman SL Singh B. Research note: HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas. Parasite Immunol 2000 22 : 469 473.
92. Daubersies P, Thomas AW, Millet P, et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000 6 : 1258 1263.
93. Aidoo M, Lalvani A, Gilbert SC, et al. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect Immun 2000 68 : 227 232.
94. Moyano EM, Gonzalez LM, Arahuetes S Benito A. Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages. Parasitol Res 2007 102 : 111 115.
95. Kumar N Carter R. Biosynthesis of the target antigens of antibodies blocking transmission of Plasmodium falciparum. Mol Biochem Parasitol 1984 13 : 333 342.
96. Escalante AA, Grebert HM, Chaiyaroj SC, et al. Polymorphism in the gene encoding the Pfs48/45 antigen of Plasmodium falciparum. XI. Asembo Bay Cohort Project. Mol Biochem Parasitol 2002 119 : 17 22.
97. Kocken CH, Milek RL, Lensen TH, Kaslow DC, Schoenmakers JG Konings RN. Minimal variation in the transmission-blocking vaccine candidate Pfs48/45 of the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 1995 69 : 115 118.
98. Conway DJ, Cavanagh DR, Tanabe K, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000 6 : 689 692.
99. Pacheco MA, Poe AC, Collins WE, et al. A comparative study of the genetic diversity of the 42 kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax. Infect Genet Evol 2007 7 : 180 187.
100. Tanabe K, Sakihama N, Nakamura Y, et al. Selection and genetic drift of polymorphisms within the merozoite surface protein-1 gene of Plasmodium falciparum 5. Gene 2000 241 : 325 331.
101. Polley SD Conway DJ. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 2001 158 : 1505 1512.
102. Hughes AL. Circumsporozoite protein genes of malaria parasites (Plasmodium spp.): evidence for positive selection on immunogenic regions. Genetics 1991 127 : 345 353.
103. Coulibaly D, Diallo DA, Thera MA, et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 2002 67 : 604 610.
104. Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW Moormann AM. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Am J Trop Med Hyg 2007 77 : 250 255.
105. Gilbert PB. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. Stat Med 2001 20 : 263 279.
106. Barclay VC, Chan BH, Anders RF Read AF. Mixed allele malaria vaccines: host protection and within-host selection. Vaccine 2008 26 : 6099 6107.
107. Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW Blackman MJ. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem 2007 282 : 7431 7441.
108. Chaudhuri R, Ahmed S, Ansari FA, Singh HV Ramachandran S. MalVac: database of malarial vaccine candidates. Malar J 2008 7 : 184.
109. Kanoi BN Egwang TG. New concepts in vaccine development in malaria. Curr Opin Infect Dis 2007 20 : 311 316.
110. Scarselli M, Giuliani MM, du-Bobie J, Pizza M Rappuoli R. The impact of genomics on vaccine design. Trends Biotechnol 2005 23 : 84 91.
111. Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008 8 : 4680 4694.
112. Doolan DL Hoffman SL. DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation. Int J Parasitol 2001 31 : 753 762.
113. Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996 64 : 3833 3844.
114. Zhou Z, Todd CW, Wohlhueter RM, et al. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum Vaccin 2006 2 : 14 23.
115. Wykes M Good MF. A case for whole-parasite malaria vaccines. Int J Parasitol 2007 37 : 705 712.
116. Luke TC Hoffman SL Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003 206 (Pt 21 3803 3808.
117. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002 360 : 610 617.
118. Uilenberg G, Silayo RS, Mpangala C, Tondeur W, Tatchell RJ Sanga HJ. Studies on Theileriidae (Sporozoa) in Tanzania. X. A large-scale field trial on immunization against cattle Theileriosis. Tropenmed Parasitol 1977 28 : 499 506. (Pubitemid 8247225)
119. Roberts L Enserink M. Malaria. Did they really say...eradication? Science 2007 318 : 1544 1545.
120. Tanner M de Savigny D. Malaria eradication back on the table. Bull World Health Organ 2008 86 : 82.